Press Release

Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program …

[Read more...] about Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma

NEW YORK and LONDON, February 11, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …

[Read more...] about Akari Therapeutics to Present at BIO CEO & Investor Conference

New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and …

[Read more...] about FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

NEW YORK and LONDON, January 4, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …

[Read more...] about Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

NEW YORK and LONDON, December 30, 2021 – Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative …

[Read more...] about Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering